Cidara Therapeutics (NASDAQ: CDTX) releases Q3 2025 financial results press

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025. The company furnished this update through a press release dated November 6, 2025, which is attached as an exhibit to the report. The filing classifies the information as furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other regulatory documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001610618false00016106182025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Cidara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36912

46-1537286

(State or Other Jurisdiction of Incorporation or Organization)

(Commission File Number)

(I.R.S. Employer Identification Number)

6310 Nancy Ridge Drive, Suite 101

San Diego, California 92121

(858) 752-6170

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

CDTX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

In this report, “Cidara Therapeutics,” “Cidara,” “Company,” “we,” “us” and “our” refer to Cidara Therapeutics, Inc.

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, we issued a press release reporting our financial results for the third quarter ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release attached as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release issued November 6, 2025, reporting financial results for the third quarter ended September 30, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Cidara Therapeutics, Inc.
Date: November 6, 2025									/s/ Jeffrey Stein, Ph.D.
									Jeffrey Stein, Ph.D.
									President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did Cidara Therapeutics (CDTX) report in this 8-K filing?

Cidara Therapeutics reported that it issued a press release on November 6, 2025, providing its financial results for the third quarter ended September 30, 2025, and furnished that press release as an exhibit.

Which period do the reported Cidara Therapeutics (CDTX) results cover?

The reported results cover Cidara Therapeutics’ financial performance for the third quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for Cidara Therapeutics (CDTX)?

The detailed third quarter 2025 results are contained in the press release attached as Exhibit 99.1 to the report.

Are the Cidara Therapeutics (CDTX) Q3 2025 results deemed filed with the SEC?

The company states that the information in the report, including the press release in Exhibit 99.1, is furnished under SEC rules and is not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the Cidara Therapeutics (CDTX) Q3 2025 results report?

The report was signed on behalf of Cidara Therapeutics, Inc. by Jeffrey Stein, Ph.D., its President and Chief Executive Officer and principal executive officer.

What exhibits are included with this Cidara Therapeutics (CDTX) 8-K?

The report includes Exhibit 99.1, a press release dated November 6, 2025 reporting third quarter 2025 financial results, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.